Written by Dentistry Today Monday, 30 January 2012 15:44
Researchers have pinpointed a genetic variation that increases the risk of developing necrotic jawbone lesions. The condition stems from bisphosphonates.
The study appeared in the online version of The Oncologist.
This research shows that a genetic screening test will be necessary to show who will be able to take these drugs in the future without awful side effects.
There are currently about 3 million women in the United States who take oral bisphosphonates. These bisphosphonates are taken to treat osteoporosis. Bisphosphonates are also taken intravenously by cancer patients.